NEW YORK, June 15 (GenomeWeb News) - AlgoNomics will use its structural bioinformatics platform to analyze antibody leads in Mat Biopharma's therapeutic development program in hematological cancer and other solid cancers, the companies said today.

 

Financial terms of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.